Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Anti-thrombotic Effects of Modified Jeho-tang using a FeCl3-induced Carotid Arterial Thrombosis Model

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2013, v.34 no.2, pp.51-58
https://doi.org/10.13048/jkm.13006






  • Downloaded
  • Viewed

Abstract

Objectives: The aim of this study was to examine the antithrombotic effects of the four herbal ingredients (Mume Fructus, MF; Santali Albi Lignum, SAL; Amomi Tsao-Ko Fructus, ATF; and Amomi Fructus, AF) of modified Jeho-tang (MJHT) in a ferric chloride (FeCl3)-induced carotid arterial thrombosis model. Methods: Thirty minutes prior to a 35% FeCl3 application, Sprague-Dawley (SD) rats were injected with saline, MF, SAL, ATF or AF (100 mg/kg, intraperitoneal injection), respectively. The effect of the MJHT ingredients was examined for time to occlusion (TTO) and thrombus weight (TW) in a FeCl3-induced thrombosis model. Histological analysis was performed to examine the effect of the MJHT ingredients on collagen fiber damage using hematoxylin & eosin and Masson’s trichrome staining. Results: Compared with vehicle treatment, MF, SAL and ATF treatment delayed TTO (vehicle, 8.11 ± 0.60 min; MF, 16.67 ± 1.03 min; SAL, 17.50 ± 1.52 min and ATF, 13.33 ± 1.21 min; P < 0.001) and inhibited thrombus formation (vehicle, 0.79 ± 0.03 mg/mm; MF, 0.61 ± 0.07 mg/mm; SAL, 0.57 ± 0.03 mg/mm and ATF, 0.72 ± 0.02 mg/mm; P < 0.001). In addition, each herbal ingredient of MJHT except for AF prevented the collagen fiber damage induced by a 35% FeCl3 application. These results indicate that the MJHT ingredients MF ≥ SAL 〉ATF 〉AF possess antithrombotic activity in a FeCl3-induced carotid arterial thrombosis. Conclusions: Altogether, these results are the first evidence that the MJHT ingredients MF, SAL and ATF have the ability to prevent vascular damage and thrombus formation in FeCl3-induced carotid arterial thrombosis.

keywords
modified Jeho-tang, FeCl3-induced carotid arterial rat model, thrombosis


Reference

1

1. Owens AP, Mackman N. Tissue factor andthrombosis: The clot starts here. ThrombHaemost. 2010;104(3): 432-9.

2

2. Rader DJ, Daugherty A. Translating moleculardiscoveries into new therapies foratherosclerosis. Nature. 2008;451(7181):904-13.

3

3. Baek KM, Roh SS. Effects of Aqueous extractof diospyros Kaki Calyx on ant-thromboticactivity in vitro and in vivo. Kor J Herblology.2011;26(4):139-47.

4

4. Leadley Jr RJ, Chi L, Rebello SS, Gagnon A.Contribution of in vivo models of thrombosis tothe discovery and development of novelantithrombotic agents. J Pharmacol ToxicolMethods. 2000;43(2):101-16.

5

5. Kurz KD, Main BW, Sandusky GE. Rat modelof arterial thrombosis induced by ferric chloride.Thromb Res. 1990; 60(4):269-80.

6

6. Konstantinides S, Schafer K, Thinnes T,Loskutoff DJ. Plasminogen activator inhibitor-1and its cofactor vitronectin stabilize arterialthrombi after vascular injury in mice. Circulation. 2001;103(4):576-83.

7

7. Elg M, Gustafsson D, Carlsson S. Antithromboticeffects and bleeding time of thrombin inhibitorsand warfarin in the rat. Thromb Res. 1999;94(3):187-97.

8

8. Schwarz M, Meade G, Stoll P, Ylanne J, BasslerN, Chen YC, et al. Conformation-specificblockade of the integrin GPIIb/IIIa: a novelantiplatelet strategy that selectively targetsactivated platelets. Circ Res. 2006; 99(1):25-33.

9

9. Iwatsuki Y, Kawasaki T, Hayashi K, Moritani Y,Nii T, Miyata K. Combined effects of a factorXa inhibitor YM466 and a GPIIb/IIIA antagonistYM128 on thrombosis and neointima formationin mice. Thromb Haemost. 2004; 92(6):1221-8.

10

10. Nishida M, Mastsuno H, Kozawa O, Ueshima S,Matsuo O, Collen D, et al. tPA, but not uPA,significantly affects antithrombotic therapy by aglycoprotein IIb/IIIa antagonist, but not by afactor Xa inhibitor. J Cardiovasc Pharmacol.2000; 36(6):770-5.

11

11. Hechler B, Magnenat S, Zighetti ML, KassackMU, Ullmann H, Cazenave JP, et al. Inhibitionof platelet functions and thrombosis throughselective or nonselective inhibition of the plateletP2 receptors with increasing doses of NF449[4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol ExpTher. 2005; 314(1):232-43.

12

12. Sohn HY, Kwon CS, Son KH, Kwon GS, RyeHY, Kun EJ. Antithrombin and ThrombosisPrevention Activity of Buckwheat Seed,Fagopyrum esculentum Moench. J Korea SocFood Sci Nutr. 2006; 35(2):132-8.

13

13. Yu JY, Jin YR, Lee JJ, Chung JH, Noh JY, YouSH, et al. Antiplatelet and antithromboticactivities of Korean Red Ginseng. Arch PharmRes. 2006; 29(10):898-903.

14

14. Dubois C, Panicot-Dubois L, Merrill-Skoloff G,Furie B, Furie BC. Glycoprotein VI-dependentand -independent pathways of thrombusformation in vivo. Blood. 2006; 107(10):3902-6.

15

15. Heo J, Donguibogam. Yoon SH, Kim HJ, editors.Korea:Donguibogam Press. 2005:1147.

16

16. Min SH, Park HO, Oh HS. A study on theproperties of water of Korean dried tangerinepeel and development of beverage by using it.Korean J Soc Food Cookery Sci. 2002;18(1):51-6.

17

17. Ji MS, Ko BS, Ahn SW, Kim JG. Abibliographical study on Jehotang. J East AsianSoc Dietary Life. 2008; 18(1): 158-64.

18

18. Ji MS, Kim JG. Analytical study on the Jehotangin Literature in terms of cooking science. J EastAsian Soc Dietary Life. 2008; 18(4):446-54.

19

19. Ji MS, Park MJ, Lee MY, Kim JG , Ko BS.Effect of Jehotang extract on the growth ofintestinal bacteria and immunostimulation.Korean J Food Sci Technol. 2006; 38: 104-8.

20

20. Jeon WK, Kim YE, Park SO, Kwon DY, AhnSW, Lee JH, et al. The modified Jeho-tang,Korean herbal medicine, inhibits whole-bloodaggregation and platelet adhesion to collagenunder flow. Thromb Res. 2008; 122(6): 804-9.

21

21. Kim SK, Jeon WK. Effects of ModifiedJeho-tang on Ferric Chloride-inducedThrombosis in a Rat Model and of PeripheralCirculatory Disturbance in a Mouse Model. JKorean Soc Appl Biol Chem. 2010; 53(6): 842-6.

22

22. Wang X, Smith PL, Hsu MY, Ogletree ML,Schumacher WA. Murine model of ferricchloride-induced vena cava thrombosis: evidencefor effect of potato carboxypeptidase inhibitor.J Thromb Haemost. 2006; 4(2): 403-10.

23

23. Heo EJ, Lee IS, Kang HW, Jeon WK. Effectsof Sokmyong-tang on Ferric choliride-inducedcarotid injury thrombosis in a rat model. KoreanJ Oriental Physiology & Pathology. 2012;26(5):732-7.

24

24. Lee IS, Chio SG, Jeon WK. Optimization offerric chloride induced carotid artery thrombosismodel in a rat: Effect of Ginkgo biloba extracts.The Korean Journal of Clinical LaboratorySciences. 2011; 43(4):179-87.

25

25. Fuster V, Kelly BB. Promoting cardiovascularhealth in the developing world (A criticalchallenge to achieve global health). Institute ofMedicine (US) Committee on Preventing theGlobal Epidemic of Cardiovascular Disease:Meeting the Challenges in Developing Countries.National Academies Press, Washington (DC).2010; 275-7.

26

26. Kim KS, Shin YW, Kim EI, Kim SM, Lee JE,Yoo DY. The experimental study onantithrombotic activities of Wuslsan. The Journalof Oriental Obstetrics & Gynecology.2005;18(3):110-26.

27

27. Sachs UJ, Nieswandt B. In vivo thrombusformation in murine models. Circ Res. 2007;100(7):979-91.

28

28. Lee IS, Kim MY, Jeon WK. Acute toxicity studyof Modified Jeho-tang in ICR mice. The KoreanJournal of clinical Laboratory Sciences. 2012;44(2):59-64.

29

29. Renne T, Pozgajova M, Gruner S, Schuh K,Pauer HU, Burfeind P, et al. Defective thrombusformation in mice lacking coagulation factor XII.J Exp Med. 2005; 202(2):271-81.

상단으로 이동

Journal of Korean Medicine